TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06680414

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supportive Vaccine Communication Using Motivational Interviewing
Description: Supportive Vaccine Communication using Motivational Interviewing will be administered to the pregnant mothers in the experimental group by the researcher. The training will take place in 3-part and 6-sessions, one week apart, and each session will last approximately 40 minutes. The training will be carried out as group training with 3-5 people. Data collection forms will be applied before and after the program.
Study: NCT06681376

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comfort menu and cart
Description: The comfort menu and cart will be implemented after the pre-intervention data collection phase is completed. The menu will list the items available on the cart and will be presented to eligible patients in printed or digital format (on a tablet). The cart will be placed in an easily accessible area within the ED. Approximated retail prices have been previously reported.~Comfort Cart Contents:~* Hot and cold packs;~* Extra blanket and pillow;~* Face towel;~* Gloves and hat;~* Personal hygiene kit;~* Items for distraction;~* Items to enhance communication.~Comfort Menu Options:~* Physiotherapy assessment;~* Conversation with chaplain, concierge, or social worker;~* List of resources for older adults needing community services;~* Home care assistance.
Study: NCT04558593

Intervention type: PROCEDURE
Intervention: Active surveillance
Description: Per standard of care: Imaging and blood tests every 6 months (3 first years) and annually (following years)

Intervention type: PROCEDURE
Intervention: Surgery
Description: Per standard of care: partial or full resection of the kidney, imaging annually
Study: NCT05181033

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib + Letrozole
Description: Patient will receive letrozole 2.5mg daily plus lenvatinib 14mg daily until disease progression/unacceptable toxicity.~Patient review, safety evaluations, thyroid function monitoring and urine dipstick will be done. Toxicities will be graded using NCI CTCAE toxicity grading vs 4.0. Patient should be discontinued if drug cannot be resumed within 28 days due to toxicities.~Drugs should be withheld when subject has imminent risk to develop hypertensive crisis/has significant risk factors for severe complications of uncontrolled hypertension. Drugs can be resumed once patient received same hypertensive medications for at least 48 hours and the BP is controlled.~Lenvatinib should be withheld for at least 1 week prior to elective surgery, at least 2 weeks after major surgery, until adequate wound healing.~For risk of ONJ, oral dental examination and preventive dentistry should be considered prior to lenvatinib intake.~There is no dose modifications for letrozole.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fulvestrant
Description: Patients will be treated with Fulvestrant 500mg injections that are administered into the muscles (intramuscularly). This is injected at 2-weekly interval for the first 3 doses, followed by 4-weekly interval dosing.
Study: NCT05333328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ovarian function suppression with endocrine treatments
Description: * Ovarian function suppression (OFS) with endocrine therapies including either tamoxifen or aromatase-inhibitors will be administered for 5 years.~* Either goserelin acetate or leuprorelin Acetate is allowed.~* These patients are able to choose bilateral salpingo-oophorectomy instead of OFS.~* Chemotherapy is omitted in these patients.
Study: NCT04710134

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Reslizumab
Description: Reslizumab 3,4, or 5 mg/kg IV q4 weeks

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Reslizumab
Description: Reslizumab 3,4, or 5 mg/kg IV q4 weeks

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Reslizumab
Description: Reslizumab 3,4, or 5 mg/kg IV q4 weeks
Study: NCT06629246

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional heart failure treatment
Description: Conventional heart failure treatment, which may include pharmacological therapies such as diuretics, ACE inhibitors/ARBs, beta-blockers, or aldosterone receptor antagonists, based on the clinical requirements of the condition.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pogejiuxin decoction combined with conventional heart failure treatment
Description: In addition to receiving standard heart failure treatment, patients are also administered Pogejiuxin Decoction.The formula of Pogejiuxin Decoction is as follows : Processed Aconite 60g (decocted initially for 1 hour), Dried Ginger 60g, Honey-fried Licorice 60g, Cornus officinalis 60g, Ginseng 30g (decocted separately), Raw Dragon Bone 30g (decocted initially for 1 hour), Raw Oyster Shell 30g (decocted initially for 1 hour), Living Magnetite 30g, for a total of 7 prescriptions. Usage: Uniformly decocted with a herbal medicine decoction machine to obtain the medicinal liquid, one prescription per day, taken twice daily in the morning and evening, each time 100ml, for a continuous treatment of 7 days.
Study: NCT06494826

Intervention type: OTHER
Intervention: colonoscopy procedure
Description: Candidates for a medically-indicated colonoscopy due to suspected new-onset CD or non-specific GI complaints or routine screening for colorectal cancer as part of primary prevention.~colonoscopy will not be done for research purposes only .

Intervention type: OTHER
Intervention: colonoscopy procedure
Description: Candidates for a medically-indicated colonoscopy due to suspected new-onset CD or non-specific GI complaints or routine screening for colorectal cancer as part of primary prevention.~colonoscopy will not be done for research purposes only .
Study: NCT06370325

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: VPOD Wireless Tens Unit
Description: The VPOD unit will deliver NMES to participants in the Intervention Group.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy
Description: Physical therapy as per standard of care.
Study: NCT04354961

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Almonertinib
Description: Almonertinib 110mg PO once daily. A cycle of treatment is defined as 21 days of once daily treatment. Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
Study: NCT06558539

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Tibial Nerve Stimulation(TTNS)
Description: Participants in this group will discontinue all relevant medications (e.g., β3-adrenergic agonists, non-selective β-adrenergic agonists, or anticholinergic drugs) at least 14 days before signing the informed consent and will not use these medications during the study period. They will receive treatment solely with wearable transcutaneous tibial nerve stimulation.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Combination Therapy
Description: Participants in this group will continue their prescribed medication regimen, which may include β3-adrenergic agonists, non-selective β-adrenergic agonists, or anticholinergic drugs, with dosages and administration unchanged throughout the study. In addition to the standard medication therapy, participants will receive wearable transcutaneous tibial nerve stimulation using a wearable device

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Medication Therapy
Description: Participants in this group will maintain their usual medication regimen, which may include β3-adrenergic agonists, non-selective β-adrenergic agonists, or anticholinergic drugs, with dosages and administration remaining consistent throughout the study. No additional interventions will be provided.
Study: NCT06400212

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary exercise test
Description: Participants undergo a cardiopulmonary exercise test following a standardised protocol used in national guidelines
Study: NCT06283524

Intervention type: DEVICE
Intervention: Eye-Tracking
Description: Eye-tracking technology and algorithms used to successfully capture and track eye movements using an electronic tablet and the embedded camera of the device.
Study: NCT06211517

Intervention type: OTHER
Intervention: Semi-structured interviews with visual mediations
Description: Semi-structured interviews with visual mediations / An hour-long interview

Intervention type: OTHER
Intervention: Semi-structured interviews with visual mediations
Description: Semi-structured interviews with visual mediations / An hour-long interview

Intervention type: OTHER
Intervention: Semi-structured interviews
Description: Semi-structured interviews
Study: NCT06370325

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physical Therapy
Description: Physical therapy as per standard of care.
Study: NCT06305403

Intervention type: DIAGNOSTIC_TEST
Intervention: serum creatinin level
Description: Serum creatinine and urine amounts will be checked for five days.
Study: NCT06370325

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biodex
Description: Used to assess strength, endurance, power, and range of motion.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biodex
Description: Used to assess strength, endurance, power, and range of motion.
Study: NCT06507735

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mannose
Description: Mannose is a sugar monomer that is important in the glycosylation of many proteins. The concentration of mannose in mammalian plasma is \~50-100 μM, which is primarily derived from N-glycan processing. Taking dietary mannose supplements can raise the levels of plasma mannose by 3- to 5-fold. There are currently no known adverse effects of mannose supplementation in humans.
Study: NCT05536479

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autogenous stored mineralized dentin graft (ASMDG)
Description: Autogenous stored mineralized dentin graft (ASMDG) particles will be prepared by immersing tooth particles in basic ethanol for 10 min for disinfection, then washed twice in saline and dried using sterile gauze.~The disinfected particles will then be stored at room temperature for 21 days in a sterile container. After 21 days, a second extraction will be performed followed by mixing the stored graft with a few drops of sterile saline to be packed in a socket after extraction

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Autogenous fresh mineralized dentin graft (AFMDG)
Description: Autogenous fresh mineralized dentin graft (AFMDG) particles will be prepared by immersing tooth particles in basic ethanol for 10 min for disinfection, then washed twice in saline and dried using sterile gauze.
Study: NCT06029660

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IMPEDE-FX RapidFill Implants
Description: Filling of the available flow lumen within the AAA sac with IMPEDE-FX RapidFill Implants

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EndoVascular Aneurysm Repair
Description: Standard EVAR repair of abdominal aortic aneurysms using a commercially available stent.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EndoVascular Aneurysm Repair
Description: Standard EVAR repair of abdominal aortic aneurysms using a commercially available stent.
Study: NCT05952310

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Natural Killer (NK) cells (a new immunotherapy)
Description: It is proposed to infuse allogeneic NK cells from a haploidentical donor, after administration of lymphoablative chemotherapy and/or radiotherapy, as a treatment in patients with sarcomas, who have completed conventional treatment but maintain detectable residual disease.~The administration of low doses of radiotherapy is aimed at stressing residual tumor cells by increasing the expression of NK cell activating receptor ligands.~The administration of prior chemotherapy aims at immunosuppressing the patient, allowing immunotherapy with allogeneic NK cells from haploidentical donor as well as autologous NK cell recovery to lead the immune reconstitution after chemotherapy, prolonging the antitumor effect.~In conjunction with NK cell infusion, low doses (1x106/UI/m2) of interleukin 2 (IL-2) will be administered subcutaneously every 48h for a maximum of 6 doses, to favor the expansion and antitumor effect of NK cells.
Study: NCT05718739

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AX6 6-axis logging accelerometer
Description: The device is collecting longitudinal movement data.
Study: NCT05708521

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Personalization of dose and frequency and instituting a tapering protocol of hydromorphone post-orthognathic surgery
Description: POP participants will be given a personalized opioid prescription with a tapering protocol based on their last inpatient 24-hour usage of opioids, obtained from the nursing medication administration record. Should a participant stay in the hospital for less than 24 hours (e.g. patient had an early discharge at 18 hours), the 24-hour in-patient opioid usage would be extrapolated from their total amount and frequency of opioid use. The participant will be provided with an instruction card with suggestions on how much opioid to take at various time points following discharge to safely taper their medication.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standardized dose and frequency of hydromorphone with no tapering post-orthognathic surgery
Description: SOP participants will be given a standardized dose of hydromorphone (2-4mg orally every 6 hours), and a total amount of 40mg. No further information is provided to them with regards to their pain medication and to tapering.
Study: NCT04978415

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peribulbar block versus subtenon's block
Description: Sixty patients undergoing vitreoretinal surgery were randomized to receive either peribulbar or sub-Tenon's capsule injection of 8 ml of a 20:80 mixture of 2% lidocaine and 0.75% bupivacaine with 60 IU hyalouronic acid.~two groups 30 patient each (group p and group s) after connecting the patient to the monitor, we give him sedation 50 mg propofol, apply a nasal cannula group P: receives 2 injection peribulbar block group S: receives single injection subtenon Patients rate their pain sensation in both groups using an 11-point (0-10) numerical visual analogue scale immediately after surgery.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peribulbar block versus subtenon's block
Description: Sixty patients undergoing vitreoretinal surgery were randomized to receive either peribulbar or sub-Tenon's capsule injection of 8 ml of a 20:80 mixture of 2% lidocaine and 0.75% bupivacaine with 60 IU hyalouronic acid.~two groups 30 patient each (group p and group s) after connecting the patient to the monitor, we give him sedation 50 mg propofol, apply a nasal cannula group P: receives 2 injection peribulbar block group S: receives single injection subtenon Patients rate their pain sensation in both groups using an 11-point (0-10) numerical visual analogue scale immediately after surgery.
Study: NCT06064617

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Contact Lens
Description: Coopervision Biofinity Multifocal Lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Contact Lens
Description: Coopervision Biofinity Multifocal Lens
Study: NCT06424002

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mosquirixs
Description: RTS,S is a subunit vaccine that includes a portion of the circumsporozoite protein (CSP) co-expressed with Hepatitis B surface antigen. The adjuvant is AS01. Three doses of the vaccine will be administered, each with one month interval.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mosquirixs
Description: RTS,S is a subunit vaccine that includes a portion of the circumsporozoite protein (CSP) co-expressed with Hepatitis B surface antigen. The adjuvant is AS01. Three doses of the vaccine will be administered, each with one month interval.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: artemether-lumefantrine
Description: A therapeutic dose of artemether-lumefantrine (20 mg of artemether and 120 mg of lumefantrine) will be given twice a day for 3 days based on the weight of the child as per treatment guidelines.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: artemether-lumefantrine
Description: A therapeutic dose of artemether-lumefantrine (20 mg of artemether and 120 mg of lumefantrine) will be given twice a day for 3 days based on the weight of the child as per treatment guidelines.
Study: NCT05138211

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exoskeleton assisted gait on a treadmill
Description: The experimental protocol is divided in three sessions. During all of them, the patient will walk on a treadmill for 6 minutes while wearing a safety harness and the robotic exoskeleton in the paretic leg.~1. - Training session: The patient will wear the robotic exoskeleton to familiarize with the action of the device.~2. - Ramp Velocity Session: the session will be divided into five trials: (a) Pre, the patient will not wear the device; (b) Free, the patient will wear the robot but it is mechanically decoupled so it will enable the free knee movement; (c) Active, the robot will assist the gait until 75% maximum gait velocity ; (d) MaxActive, the robot will assist the gait until maximum gait velocity ; and (e) Post, the patient will repeat the Pre condition. Velocity will increase from comfortable velocity to the maximum and then come back to the comfortable one.~3. - Random Velocity session: the session will be divided into the same trials than the Ramp Velocity Session.
Study: NCT05556798

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belantamab Mafodotin
Description: Belantamab mafodotin will be administered via IV infusion in an outpatient setting on Day 1 of Cycles 1-3. Treatment with belantamab mafodotin will be given at an initial dose of 1.0 mg/kg. The study will have a 3+3 dose escalation design for belantamab mafodotin. Belantamab mafodotin dose levels are 1.0 mg/kg, 1.4 mg/kg, and 1.9 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nirogacestat
Description: 1:1 randomization between nirogacestat 100mg BID or 100 mg QD during the 4 day run-in period. Treatment with nirogacestat will be 100mg BID continuously during each cycle for all subjects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: After the 4-day run-in period, all patients will receive nirogacestat in combination with belantamab, mafodotin and pomalidomide. Pomalidomide was added for day 1-14 for cycle 1-3 and day 1-14 and day 21-35 for C4+.
Study: NCT06085794

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic combined intrarenal surgery
Description: Combined complex stone clearance with mini-nephroscope and flexible URS

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous nephrolithotomy
Description: Clearance of renal stone with nephroscope in prone position
Study: NCT05803629

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 68Ga-FAPI
Description: Intravenous injection of one dosage of 74-148 MBq(2-4 mCi) 68Ga-FAPI.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 18F-FDG
Description: Intravenous injection of one dosage of 7.4MBq/kg(0.2mCi/kg) 18F-FDG. 18F-FDG PET/CT is performed within one week from 68Ga-FAPI PET/CT scan.
Study: NCT06100939

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Riboflavin and Sodium Iodide solution and Ultraviolet-A treatment
Description: Drug: Ribostat riboflavin and sodium iodide ophthalmic solution~Device: UV-3000 ultraviolet A light source

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo and sham treatment
Description: Drug: placebo ophthalmic solution~Device: UV-3000 light source
Study: NCT05855226

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OTHER-intervention (Occupational Therapy at Home E-Rehabilitation)
Description: The occupational therapist will use activity monitoring and coaching techniques with videoconference during OTHER.
Study: NCT05667753

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MINISTOP 3.0
Description: MINISTOP 3.0 is a behavioral changed program with the overall aim to promote healthier lifestyle behaviors (i.e., diet, physical activity, and sedentary behavior) among 2.5/3-year old children. The MINISTOP 3.0 program consists of features such as information, monitoring, and feedback (dietary variables, physical activity, and screen time) and is built around 13 themes over a 6-month period.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MINISTOP 3.0
Description: MINISTOP 3.0 is a behavioral changed program with the overall aim to promote healthier lifestyle behaviors (i.e., diet, physical activity, and sedentary behavior) among 2.5/3-year old children. The MINISTOP 3.0 program consists of features such as information, monitoring, and feedback (dietary variables, physical activity, and screen time) and is built around 13 themes over a 6-month period.
Study: NCT05997901

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Varenicline healthbot
Description: The intervention is a healthbot that will provide information, reminders, answers to questions, and support to participants using varenicline for smoking cessation.
Study: NCT04725006

Intervention type: DEVICE
Intervention: Spinal cord stimulation system
Description: These systems are indicated as an aid in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with the following: failed back surgery syndrome, intractable low back pain and leg pain. Stimulation will be applied to the system using an external stimulator to see if sensations can be evoked in the participant's limb/foot.
Study: NCT05102942

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attentional Control Training Program
Description: The 268 patients fulfilling the eligibility criteria will be randomized to one of the three groups: Group A: AACTP delivered via a smartphone application + treatment as usual (TAU; n = 134), or Group B: ACTP sham training delivered via a smartphone application + TAU (n = 134) Patients in Group A will receive seven sessions of AACTP (one session per week for seven weeks). Patients in Group B will receive seven sessions of sham training (one session per week for seven weeks).

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Attentional Control Training Program
Description: The 268 patients fulfilling the eligibility criteria will be randomized to one of the three groups: Group A: AACTP delivered via a smartphone application + treatment as usual (TAU; n = 134), or Group B: ACTP sham training delivered via a smartphone application + TAU (n = 134) Patients in Group A will receive seven sessions of AACTP (one session per week for seven weeks). Patients in Group B will receive seven sessions of sham training (one session per week for seven weeks).